Verweise
- FoundationOne®CDx Technical Specifications, 2021. www.foundationmedicine.com/test/foundationone-cdx (Accessed Feb 2022).
- FoundationOne®Liquid CDx Technical Specifications, 2021. https://www.foundationmedicine.com/test/foundationone-liquid-cdx (Accessed Feb 2022).
- FoundationOne®Heme Technical Specifications, 2021. www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed Feb 2022).
- Frampton GM et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;11:1023-31.
- Woodhouse R et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One. 2020;15(9):e0237802. Published 2020 Sep 25.
- Clark TA et al. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. J Mol Diagn. 2018;20(5):686-702.
- He J et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood. 2016;127(24):3004-3014.
- Suh JH et al. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials Oncologist 2016; 21: 684–691.
- Chalmers ZR et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
- Rozenblum AB et al. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. J Thorac Oncol. 2017;12(2):258-268.
- Schrock AB et al. Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing Clin Cancer Res 2016; 22: 3281–3285.
- Ross JS et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol. 2013;130(3):554-559.
- Hall MJ et al. Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP). J Clin Oncol. 2016; 34(15): 1523-1523.
- FoundationOne®CDx Sample Report. Available at: FoundationOne®CDx Beispielbericht Lungenkarzinom (Accessed March 2022).
- A search for "Foundation Medicine"[Affiliation] on the NCBI database resulted in 740 publications, as of April 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=%22Foundation+Medicine%22%5BAffiliation%5D (Accessed August 2020).
- Foundation Medicine Publications. Available at: https://www.foundationmedicine.com/publications (Accessed March 2019).
- FoundationOne®CDx FDA Approval, 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed March 2019).
- Milbury, Coren A et al. “Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.” PloS one vol. 17,3 e0264138. 16 Mar. 2022.
- FoundationOne Liquid CDx FDA Approval, 2020. Available at: www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721 (Accessed August 2020).
- Dong L et al. Clinical next generation sequencing for precision medicine in cancer. Curr Genomics 2015; 16(4): 253–263.
- Drilon A et al. Broad, hybrid capture–based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 2015; 21(16): 3631–3639.